Lv1
50 积分 2024-06-17 加入
Review for "Preclinical and first-in-human evaluation of ribupatide (HRS9531), a dual GLP-1/GIP receptor agonist"
1个月前
已关闭
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO)
1个月前
已完结
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
7个月前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
8个月前
已完结
Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
8个月前
已完结
Potential eye disorders in people with and without Type 2 diabetes mellitus exposed to GLP-1 receptor agonists; an examination of the FAERS (FDA Adverse Event reporting System) database
10个月前
已完结
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial
11个月前
已完结
The relationship between obesity and chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
11个月前
已完结
Mechanisms of diabetic kidney disease and established and emerging treatments
11个月前
已完结
皖公网安备34019202002308
